View in EDS PDF Full Text

ANTIINFECCIOSOS DE USO SISTÉMICO FALSIFICADOS Y SUBESTÁNDARES EN PERÚ.

Saved in:
Bibliographic Details
Title: ANTIINFECCIOSOS DE USO SISTÉMICO FALSIFICADOS Y SUBESTÁNDARES EN PERÚ.
Alternate Title: SUBSTANDARD AND FALSIFIED SYSTEMIC ANTI-INFECTIVES IN PERU.
Authors: Huamaní-Pacsi, Carlos1 chuamani.ins@gmail.com, Torres Olivera, Roberto2
Source: Revista Peruana de Medicina Experimental y Salud Pública. 2026, Vol. 43 Issue 2, p224-230. 7p.
Abstract (English): Substandard and falsified (SF) systemic anti-infective (SAI) medications detected by the National Health Authority of Peru between 2015 and 2023 were quantified and characterized. An observational, descriptive, and retrospective design was applied, based on test reports issued by the National Quality Control Center on the quality of SAIs, complemented with national evidence of antimicrobial resistance (AMR). Of 9799 pharmaceutical products evaluated, 1247 (12.7%) were SF; of these, 189 (15.2%) corresponded to SF SAIs, with falsified ones predominating (11.0%). The main groups were β-lactams (27.5%), sulfonamides/trimethoprim (26.5%), and quinolones (12.7%). 59.8% had informal origin, mostly from Lima (72%). The circulation of SF SAI medications could promote selective pressure, the spread of AMR, and therapeutic failure. [ABSTRACT FROM AUTHOR]
Abstract (Spanish): Se cuantificó y caracterizó medicamentos antiinfecciosos de uso sistémico (AUS) subestándares y falsificados (SF) pesquisados por la Autoridad Sanitaria Nacional del Perú entre 2015 y 2023. Se aplicó un diseño observacional, descriptivo y retrospectivo basado en informes de ensayo emitidos por el Centro Nacional de Control de Calidad sobre calidad de los AUS, complementados con evidencia nacional de resistencia antimicrobiana (RAM). De 9799 productos farmacéuticos evaluados, 1247 (12,7%) fueron SF; de estos, 189 (15,2%) correspondieron a AUS SF, predominando los falsificados (11,0%). Los principales grupos fueron β-lactámicos (27,5%), sulfonamidas/trimetoprima (26,5%) y quinolonas (12,7%). El 59,8% tuvieron procedencia informal, mayormente de Lima (72%). La circulación de medicamentos AUS SF podría favorecer la presión selectiva, propagación de la RAM y el fracaso terapéutico. [ABSTRACT FROM AUTHOR]
Copyright of Revista Peruana de Medicina Experimental y Salud Pública is the property of Instituto Nacional de Salud (Peru) and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: MedicLatina
FullText Links:
  – Type: pdflink
Text:
  Availability: 0
Header DbId: lth
DbLabel: MedicLatina
An: 195382616
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: ANTIINFECCIOSOS DE USO SISTÉMICO FALSIFICADOS Y SUBESTÁNDARES EN PERÚ.
– Name: TitleAlt
  Label: Alternate Title
  Group: TiAlt
  Data: SUBSTANDARD AND FALSIFIED SYSTEMIC ANTI-INFECTIVES IN PERU.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Huamaní-Pacsi%2C+Carlos%22">Huamaní-Pacsi, Carlos</searchLink><relatesTo>1</relatesTo><i> chuamani.ins@gmail.com</i><br /><searchLink fieldCode="AR" term="%22Torres+Olivera%2C+Roberto%22">Torres Olivera, Roberto</searchLink><relatesTo>2</relatesTo>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Revista+Peruana+de+Medicina+Experimental+y+Salud+Pública%22">Revista Peruana de Medicina Experimental y Salud Pública</searchLink>. 2026, Vol. 43 Issue 2, p224-230. 7p.
– Name: Abstract
  Label: Abstract (English)
  Group: Ab
  Data: Substandard and falsified (SF) systemic anti-infective (SAI) medications detected by the National Health Authority of Peru between 2015 and 2023 were quantified and characterized. An observational, descriptive, and retrospective design was applied, based on test reports issued by the National Quality Control Center on the quality of SAIs, complemented with national evidence of antimicrobial resistance (AMR). Of 9799 pharmaceutical products evaluated, 1247 (12.7%) were SF; of these, 189 (15.2%) corresponded to SF SAIs, with falsified ones predominating (11.0%). The main groups were β-lactams (27.5%), sulfonamides/trimethoprim (26.5%), and quinolones (12.7%). 59.8% had informal origin, mostly from Lima (72%). The circulation of SF SAI medications could promote selective pressure, the spread of AMR, and therapeutic failure. [ABSTRACT FROM AUTHOR]
– Name: Abstract
  Label: Abstract (Spanish)
  Group: Ab
  Data: Se cuantificó y caracterizó medicamentos antiinfecciosos de uso sistémico (AUS) subestándares y falsificados (SF) pesquisados por la Autoridad Sanitaria Nacional del Perú entre 2015 y 2023. Se aplicó un diseño observacional, descriptivo y retrospectivo basado en informes de ensayo emitidos por el Centro Nacional de Control de Calidad sobre calidad de los AUS, complementados con evidencia nacional de resistencia antimicrobiana (RAM). De 9799 productos farmacéuticos evaluados, 1247 (12,7%) fueron SF; de estos, 189 (15,2%) correspondieron a AUS SF, predominando los falsificados (11,0%). Los principales grupos fueron β-lactámicos (27,5%), sulfonamidas/trimetoprima (26,5%) y quinolonas (12,7%). El 59,8% tuvieron procedencia informal, mayormente de Lima (72%). La circulación de medicamentos AUS SF podría favorecer la presión selectiva, propagación de la RAM y el fracaso terapéutico. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of Revista Peruana de Medicina Experimental y Salud Pública is the property of Instituto Nacional de Salud (Peru) and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=lth&AN=195382616
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.17843/rpmesp.2026.432.1557
    Languages:
      – Code: spa
        Text: Spanish
    PhysicalDescription:
      Pagination:
        PageCount: 7
        StartPage: 224
    Titles:
      – TitleFull: ANTIINFECCIOSOS DE USO SISTÉMICO FALSIFICADOS Y SUBESTÁNDARES EN PERÚ.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Huamaní-Pacsi, Carlos
      – PersonEntity:
          Name:
            NameFull: Torres Olivera, Roberto
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 04
              Text: 2026
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-print
              Value: 17264634
          Numbering:
            – Type: volume
              Value: 43
            – Type: issue
              Value: 2
          Titles:
            – TitleFull: Revista Peruana de Medicina Experimental y Salud Pública
              Type: main
ResultId 1